FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Liquidia Expects FDA Yutrepia Final OK Soon

[ Price : $8.95]

Liquidia says it believes there no longer are legal bars on FDA approving its Yutrepia inhalation powder for two indications.

Novartis Seeking Expanded Pluvicto Label

[ Price : $8.95]

Novartis says it will seek FDA approval for an expanded use for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for slowing disea...

FDA Cross-Center AI Paper Analyzed

[ Price : $8.95]

Hogan Lovells attorneys say FDA may create new Centers of Excellence as it works to regulate AI in medical product development thr...

Califf in Hot Seat at 4/11 Oversight Hearing

[ Price : $8.95]

The House Committee on Oversight and Accountability ratchets up political pressure on FDA by requesting commissioner Robert Califf...

Amylyx Pulls ALS Drug From the Market

[ Price : $8.95]

Amylyx Pharmaceuticals withdraws the approval of its amyotrophic lateral sclerosis drug Relyvrio (sodium phenylbutyrate and taurur...

Guide on Dietary Supplement Master Files

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance entitled New Dietary Ingredient Notification Master Files for Dietar...

Smiths Medical Recalls PneuPac Ventilator Kits

[ Price : $8.95]

Smiths Medical recalls its PneuPac paraPAC Plus 300 and 310 Ventilator Kits after receiving reports that the device may malfunctio...

Ignore Former FDAers Comments: Sidley

[ Price : $8.95]

A Sidley petition comment response asks FDA to disregard comments on Sidleys orphan drug exclusivity petition made by former FDA o...

New Indication for Vandas Fanapt

[ Price : $8.95]

FDA approves a new indication for Vandas Fanapt to treat some adults with bipolar I disorder.

Bipartisan Bill on Drug-Gene Interactions

[ Price : $8.95]

Representatives Eric Swalwell (D-CA) and Dan Crenshaw (R-TX) introduce bipartisan legislation to help address drug-gene interactio...